title: Targinact for restless legs syndrome.
abstract: Idiopathic restless legs syndrome (RLS)--also known as Willis-Ekbom disease--is a neurological condition characterised by an overwhelming urge to move the legs, occurring during rest or inactivity, especially at night. Symptoms are highly variable in frequency and severity, and can affect sleep and quality of life. First-line management includes addressing precipitating or aggravating factors and providing explanation, reassurance and advice on self-help strategies. Drug therapy (e.g. a dopamine agonist) is used for patients with more severe symptoms. In December 2014, the marketing authorisation for a modified-release preparation containing oxycodone and naloxone (Targinact-Napp Pharmaceuticals) was expanded to include use in the treatment of severe to very severe RLS after failure of dopaminergic therapy.(10)Here we review the management of adults with RLS, including the place of oxycodone/naloxone.
mesh_terms: D000701:Analgesics, Opioid / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D009270:Naloxone / Q000009:adverse effects / Q000627:therapeutic use*; D010098:Oxycodone / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012148:Restless Legs Syndrome / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D018491:Dopamine Agonists; D004338:Drug Combinations; C557247:oxycodone naloxone combination; D009270:Naloxone; D010098:Oxycodone